NEW YORK, NY / ACCESSWIRE / September 23, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
ABT Shareholders Click Here: https://www.zlk.com/pslra-1/abbott-laboratories-class-action-lawsuit-submission-form?prid=32098&wire=1
SMFR Shareholders Click Here: https://www.zlk.com/pslra-1/sema4-lawsuit-loss-submission-form?prid=32098&wire=1
FLGT Shareholders Click Here: https://www.zlk.com/pslra-1/fulgent-genetics-lawsuit-loss-submission-form?prid=32098&wire=1
* ADDITIONAL INFORMATION BELOW *
Abbott Laboratories (NYSE:ABT)
This lawsuit is on behalf of all persons or entities who purchased or otherwise acquired shares of Abbott common stock during the period from February 19, 2021, to June 8, 2022, inclusive.
Lead Plaintiff Deadline : October 31, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abbott-laboratories-class-action-lawsuit-submission-form?prid=32098&wire=1
According to the filed complaint, defendants touted the strength of Abbott's infant formula brands and their contribution to the Company's sales and revenue growth, despite knowing that the facility that manufactured those products was in flagrant violations of United States Food and Drug Administration ("FDA") health, safety, and manufacturing regulations. The complaint further alleges that defendants willfully or recklessly concealed these violations from investors, even though the violations put Abbott's infant formula business in dire jeopardy and left the Company exposed to a risk of severe regulatory action, including the recall of its products and closure of the Sturgis facility. Indeed, according to the complaint, defendants received direct warnings, communications, FDA inspection reports, and consumer complaints identifying in detail the safety and regulatory violations that were rampant at the Sturgis facility.
Sema4 Holdings, Corp. (NASDAQ:SMFR)
SMFR Lawsuit on behalf of: investors who purchased March 14, 2022 - August 15, 2022
Lead Plaintiff Deadline : November 7, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sema4-lawsuit-loss-submission-form?prid=32098&wire=1
According to the filed complaint, during the class period, Sema4 Holdings, Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) there was a significant risk that Sema4 would reverse a material amount of previously recognized revenue that it could not recoup from third party payors; (2) the Company was experiencing declining selling prices for its reproductive health segment; (3) as a result of the foregoing, Sema4's financial results would be adversely affected; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Fulgent Genetics, Inc. (NASDAQ:FLGT)
FLGT Lawsuit on behalf of: investors who purchased March 22, 2019 - August 4, 2022
Lead Plaintiff Deadline : November 21, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fulgent-genetics-lawsuit-loss-submission-form?prid=32098&wire=1
According to the filed complaint, during the class period, Fulgent Genetics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent's revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (iv) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE : Levi & Korsinsky, LLP